56 results about "Regulatory molecules" patented technology

The invention provides human regulatory molecules and polynucleotides (collectively designated HRM) which identify and encode them. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing, preventing, and treating disorders associated with expression of human regulatory molecules.

The present invention provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to immunoresponsive cells bearing antigen receptors, which can be chimeric antigen receptors (CARS), which express introduced ligands for immunomodulatory molecules. In particular embodiments, engineered immunoresponsive cells are antigen-directed and resist immunosuppression and / or have enhances immune-activating properties.

The present invention relates to a novel isolated leafhopper ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the leafhopper ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation system and methods for identifying molecules that modulate leafhopper ecdysone receptor activity.

Disclosed herein are antigen-binding molecules, such as antibodies, that specifically recognize a portion of the EGFR C-terminal (intracellular) regulatory domain that interacts with one or more regulatory molecules (such as Suppressor of Cytokine Signaling (“SOCS”) proteins). In certain normal or neoplastic cells and / or tissues, this region is inaccessible to the disclosed antigen-binding molecules. Thus, such antigen-binding molecules are useful at least to interrogate the regulated state of EGFR, predict the response of a cancer patient to EGFR inhibitor therapies, and / or predict the aggressiveness of neoplasms.

Aptamer oligonucleotides specifically bind to the DNA binding site of proteins such as Sp1 and Sp1-related proteins which regulate the genes which encode costimulatory molecules such as CD28 and cytokines such as IL-2 and GMCSF. The oligonucleotides compete with the DNA-binding sites of regulatory proteins which specifically regulate molecules to modulate T-cell activation. This serves to modulate gene expression by preventing transcription of the gene. Aptamers are administered to provide therapies for diseases which involve aberrant T-cell activation such as psoriasis, Type I (insulin-dependent) diabetes mellitus, multiple sclerosis, autoimmune uveitis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease (Crohn's and ulcerative colitis), and septic shock and to regulate normal T-cell activation such as in allograft rejection.

The present invention generally provides a means to control stem cell self-renewal and differentiation. More particularly, the current invention is directed toward the elucidation of a signal transduction pathway that controls the expression of a gene necessary for differentiation of stem daughter cells. By modulating the levels of key regulatory molecules within this pathway, the fate of stem cell self-renewal and differentiation may be controlled. In addition, the present invention also provides mutant organisms, tissues, cells, as well methods where the level of key molecules within the pathway are modulated.

Polynucleotides encoding a nonfunctional mutant form of the Brother of Regulator of Imprinted Sites (BORIS) molecule, nonfunctional mutated BORIS protein, polypeptide or peptide and modified protein forms of BORIS are described. These molecules are used as a therapeutic vaccine against cancer.

Provided are a modified laminin having a cell-growth regulatory molecule bound to at least one site selected from the α chain N-terminus, the α chain C-terminus, the β chain N-terminus and the δ chain N-terminus of laminin or a heterotrimeric laminin fragment, a method for culturing cells in the presence of the modified laminin, a method for establishing iPS cells in the presence of the modified laminin, and a culture substrate coated with the modified laminin. Human stem cells cultured in a xeno-free environment with the use of the modified laminin of the present invention can be provided as highly safe human stem cells applicable to regenerative medicine.

The present invention relates to a novel isolated whitefly ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the whitefly ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation system and methods for identifying molecules that modulate whitefly ecdysone receptor activity.

A targeted composition comprising a modulation molecule, such as an siRNA oligo or a small molecule, and a translocation peptide is disclosed. Methods of making and using the composition are also disclosed. The disclosed composition can be employed in a variety of therapeutic and research applications, in which it is desirable to deliver a modulation molecule, such as an siRNA oligo or a small molecule, to a particular site, such as a site of vascularization. In one aspect of a composition of the invention, a translocation peptide directs the modulation molecule to a selected location, and a modulation molecule modulates the expression or activity of a selected target disposed at or near the selected location.

The invention discloses a novel functional material based on diazosulfide and application thereof. The material is a liquid crystal luminescent material prepared by taking a diazosulfide rigid unit asa luminescent core and introducing an alkyl chain or a liquid crystal element into the lateral part of a molecular rigid skeleton. Through the structure, luminescence property can be adjusted by adjusting the energy gaps of group regulatory molecules at two ends of the luminescent core unit; the liquid crystal element on the side wall of the molecular structure is capable of effectively regulating and controlling the liquid crystal property, so that a high-efficiency liquid crystal luminescent material can be acquired; the material has abundant photophysical performance; the luminescent color of the material changes along with the change of external conditions; when the material is used as a luminescent layer dopant for preparing an organic light-emitting device, the maximal external quantum efficiency of device is 1.20%.

Disclosed herein are methods for regulation of fat and / or cholesterol uptake from the gastrointestinal tract and / or regulation of plasma fat and / or cholesterol levels comprising administering to a mammal in need thereof an effective amount of a regulator of pancreatic IB PLA2 functionality. Also disclosed herein are methods of regulating the function of a polypeptide of interest comprising inserting of the 62-66 loop region of a pancreatic IB PLA2 amino acid sequence into the polypeptide of interest; and administering an effective amount of a regulatory molecule that effects its regulation through said amino acid sequence. Further disclosed are novel bile salt compounds that regulate pancreatic IB PLA2. Methods for detecting altered pancreatic IB PLA2 function and methods for identifying an agent suitable for regulating pancreatic IB PLA2 enzyme functionality are also disclosed.

The invention relates to methods and compositions for transferring genetic material into a cell and regulating expression of the transferred genetic material. Included in the invention are methods for inducing the regulated expression of an exogenous nucleic acid introduced in a cell by the use of a regulator molecule that binds to a protein encoded by a second nucleic acid that has also been introduced into the cell.

Recombinant respiratory syncytial virus (RSV) are provided which express one or more immune modulatory molecules. The recombinant virus is modified by addition or substitution of a polynucleotide sequence encoding the immune modulatory molecule, which is preferably a cytokine. Introduction of the cytokine increase, decrease, or otherwise enhances aspects of viral biology and / or host immune responses to RSV to facilitate vaccine use of the virus. Cytokines for use within the invention include but are not limited to interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), or interleukin 18 (IL-18), tumor necrosis factor (TNF) alpha, interferon gamma (IFN), and granulocyte-macrophage colony stimulating factor (GM-CSF). The polynucleotide or immune modulatory molecule is preferably added or substituted into the recombinant viral genome or antigenome, typically at an intergenic or other non-coding site, as a separate gene but may be otherwise expressed, for example as a fusion protein.

The invention relates to anti-inflammation effect and application of an immuno-regulatory molecule Rhbdd3, in particular to protein 3 (namely Rhbdd3) or Rhbdd3 coding sequence having an rhomboid structure domain and application of promoter or inhibitor in preparation of drug used for regulating and controlling dendritic cell activation and / or inflammatory factor level or a reagent box, and further relates to application and an application method of the above substance in resisting infection and treating chronic inflammatory diseases caused by infection and corresponding drug, drug combination or reagent box. The immuno-regulator molecule can be used for inhibiting activation of infected dendritic cells and excessive generation of inflammatory factors, increasing survival rate and survival time of organisms in endotoxic shock and protecting visceral organs like lung after being infected from inflammatory damage or can be used for immunoregulation, and has wide application prospect.

Disclosed is agroup of chimeric antigen receptors (CARs) consisting of two, three or four CAR molecules, wherein the members of the group of CARs can be different or identical in their amino acid sequences to one another, and wherein each of the CAR molecules of the group comprise at least a transmembrane domain and an ectodomain comprising either an antigen binding moiety or a binding site to which another polypeptide is able to bind, wherein the another polypeptide comprises an antigen binding moiety; wherein each CAR molecule of the group comprises at least one dimerization domain, wherein this dimerization of a pair of dimerization domains is either induced by a regulating molecule and optionally reduced by another regulating molecule, or occurs in the absence of a regulating molecule and is reduced by a regulating molecule, and wherein the ectodomain of each CAR molecule of the group in its prevalent conformation is free of cysteine amino acid moieties which are able to form intermolecular disulphide bonds with other CAR molecules of the group, respectively, and wherein the antigen binding moieties of the CAR molecules of the group and of the other polypeptides being able to bind to the CAR molecules of the group are either specific for one target antigen or for a non-covalent or a covalent complex of different target antigens.

The invention provides human transcriptional regulator molecules (HTRM) and polynucleotides which identify and encode HTRM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of HTRM.

The invention provides an application of a Rac1 activity inhibitor in preparation of drugs for treating an Alzheimer disease. The Rac1 activity inhibitor can be: at least one of EHop-016, CS7171, JKF-034, Secramine, AZD0530, NSC23766, MBQ-167, AZA1, AZA197, Compound 19, ZINC08010136, ZINC07949036, 69391, 1A-116, ITX3, ITX1, CPYPP, GGTase1inhibitor(P61A6, Statins), EHT1864, Compound 1, MLS000532223, R-Ketorolac, OSU-3012, FL172, FRAX597, Phox-11, 187-1 and Wiskostatin. The invention protects the discovery of a mechanism for treating AD by inhibiting the activity of a forgetting regulatory molecule Rac1, and protects the application of a small molecule compound capable of inhibiting Rac1 activity in treating AD.

Application to an allograft or xenograft of a low strength electric field network (LSEN) together with an immuno-suppressive drug, gene and siRNA or other gene-based therapy is used to mediate the immune responses within an donor organ, tissue or cells, to prevent the acute and chronic rejection and to induce true tolerance, The gene(s) is locally transferred ex vivo in the time interval between harvest and implantation of allografts or xenografts before the implantation to introduce the long-term over expression of immunosuppressive and / or modulative molecules, or for down regulating alloreactive molecules in the donor organ, tissue or cells only and not in the recipient's whole body system.

The present invention provides an improved, expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule in the cells of a subject, for use in the treatment of disease. In particular, the present invention provides an improved, regulated gene expression system, and pharmaceutical compositions and uses thereof for treatment of disease.

The invention relates to a CAR-T cell containing an unstable structural domain, a preparation method thereof and a method for adjusting functions of the CAR-T cell. An encoding gene in the unstable structural domain is contained in the CAR-T cell; a 3' end of CAR gene without a termination codon is directly connected with the encoding gene in the unstable structural domain, so as to form a fusiongene; a fusion protein encoded by the fusion gene is expressed in the CAR-T cell; a CAR molecule exists on a N end of the fusion protein; the unstable structural domain is on a C end and is located oncytomembrane. The preparation method for the CAR-T cell containing the unstable structural domain provided by the invention has few processes and easy steps and is convenient for industrialization. According to the method for adjusting the functions of the CAR-T cell containing the unstable structural domain disclosed by the invention, the quantity of CAR molecules can be adjusted by only addinga small molecule compound corresponding to the unstable structural domain. The existence of the unstable structural domain has no influence on the functions of the CAR molecules.

The present invention provides a dendritic cell modulatory molecule which modulates, and preferable inhibits, the differentiation and maturation of mammalian dendritic cells. The invention also provides pharmaceutical compositions comprising the dendritic cell modulatory molecule and homologues and active fragments thereof, antibodies thereto and methods of treatment and screening methods which utilise such molecules.

Provided are a modified laminin having a cell-growth regulatory molecule bound to at least one site selected from the α chain N-terminus, the α chain C-terminus, the β chain N-terminus and the γ chain N-terminus of laminin or a heterotrimeric laminin fragment, a method for culturing cells in the presence of the modified laminin, a method for establishing iPS cells in the presence of the modified laminin, and a culture substrate coated with the modified laminin. Human stem cells cultured in a xeno-free environment with the use of the modified laminin of the present invention can be provided as highly safe human stem cells applicable to regenerative medicine.

A therapeutic model for the expedient treatment of deadly pathogens involved in pandemics and bioterrorism related events. The immune pathogenesis of deadly pathogens is redefined in the light of Recent advances in the Fundamentals of Immunology by developing three dimensional understandings of deadly pathogens and its interactions with host and its immune system. The immune pathogenesis of deadly pathogens can be treated expediently and globally with NSPS to mitigate the threat of bioterrorism and pandemics. According to a method for treating deadly pathogens having an immune regulatory molecule, the first step is providing a nano-engineered formulation of sodium polystyrene sulfonate (NSPS) having particle size less than 100 nm. A pharmaceutically effective dose of the NSPS is administered to a patient infected with the pathogen. The immune regulatory molecule is targeted with the NSPS for inhibiting serine protease activation. The therapeutic model is further extended for quarantine purposes to facilitate decontamination measures for patients, hospitals and laboratories.

A group of chimeric antigen receptors (CARs) having two, three or four CAR molecules,wherein the members of the group of CARs can be different in their amino acid sequences, andwherein each of the CAR molecules of the group includes at least a transmembrane domain and an ectodomain comprising either an antigen binding moiety or a binding site to which another polypeptide is able to bind, wherein the polypeptide comprises an antigen binding moiety;wherein each CAR molecule of the group includes at least one dimerization domain, wherein this dimerization of a pair of dimerization domains is either induced by a regulating molecule and optionally reduced by another regulating molecule, or occurs in the absence of a regulating molecule and is reduced by a regulating molecule, andwherein the antigen binding moieties of the CAR molecules of the group specific for one target antigen.

The invention provides a purpose of a reagent in preparation of a kit. The reagent is used for overexpressing a MIB1 gene, and the kit is used in at least one of the following: inducing cell epithelial-mesenchymal transition; obtaining mesenchymal cells; and obtaining cells highly sensitive to a ferroptosis pathway. The inventors find that after overexpressing the MIB1 gene, the cells can efficiently realize epithelial-mesenchymal transition, and the mesenchymal cells can be effectively obtained, The mesenchymal cells are highly sensitive to the ferroptosis pathway and are suitable for high-throughput screening of small molecule compounds and other regulatory molecules that are effective in inducing ferroptosis in mesenchymal cells.